home / stock / snynf / snynf quote
Last: | $94.63 |
---|---|
Change Percent: | 100.0% |
Open: | $0 |
Close: | $94.63 |
High: | $0 |
Low: | $0 |
Volume: | 52 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$94.63 | $0 | $94.63 | $0 | $0 | 52 | 05-31-2024 |
$94.63 | $94.63 | $94.63 | $94.63 | $94.63 | 1,338 | 05-30-2024 |
$100 | $0 | $100 | $0 | $0 | 77 | 05-29-2024 |
$100 | $0 | $100 | $0 | $0 | 108 | 05-28-2024 |
$100 | $0 | $100 | $0 | $0 | 652 | 05-24-2024 |
$100 | $100 | $100 | $100 | $100 | 270 | 05-23-2024 |
$100.55 | $100.18 | $100.55 | $100.55 | $100.18 | 448 | 05-22-2024 |
$97.7 | $97.7 | $97.7 | $97.7 | $97.7 | 307 | 05-21-2024 |
$96.76 | $97.32 | $96.76 | $97.32 | $96.76 | 264 | 05-20-2024 |
$97.998 | $97.998 | $97.998 | $97.998 | $97.998 | 223 | 05-17-2024 |
$96.83 | $0 | $96.83 | $0 | $0 | 262 | 05-16-2024 |
$96.83 | $97.462 | $96.83 | $97.462 | $96.83 | 729 | 05-15-2024 |
$97.65 | $97.65 | $97.65 | $97.65 | $97.65 | 568 | 05-14-2024 |
$102.52 | $0 | $102.52 | $0 | $0 | 168 | 05-13-2024 |
$102.52 | $100.9375 | $102.52 | $102.52 | $100.9375 | 2,554 | 05-10-2024 |
$99.25 | $101.4556 | $99.25 | $101.5 | $99.25 | 1,189 | 05-09-2024 |
$101.5 | $101.5 | $101.5 | $101.5 | $101.5 | 676 | 05-08-2024 |
$101.5 | $100.468 | $101.5 | $101.5 | $100.468 | 743 | 05-07-2024 |
$96.652 | $96.652 | $96.652 | $96.652 | $96.652 | 159 | 05-06-2024 |
$100 | $0 | $100 | $0 | $0 | 150 | 05-03-2024 |
News, Short Squeeze, Breakout and More Instantly...
Sanofi launches 2024 global Employee Stock Purchase Plan Paris, May 31, 2024. Sanofi’s global employee shareholder plan, Action 2024, opens on June 4, 2024, to around 80,000 employees in 56 countries. Now in its 10 th year, the program demonstrates the ongoing commitment of S...
Sanofi completes acquisition of Inhibrx, Inc. Paris, May 30, 2024. Sanofi announced today the completion of its acquisition of Inhibrx, Inc . (“Inhibrx”). The acquisition adds SAR447537 (formerly INBRX-101) to Sanofi’s rare disease pipeline, underscoring the com...
Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed multiple myeloma FDA Priority Review granted based on positive results from IMROZ phase 3 study If approved, Sarclisa would be the first anti-CD38 therapy in combination with stand...